Table 3. Characteristic clinical and... | American Society of Hematology

Table 3.

Characteristic clinical and immunophenotypic features of various types of CTCL

	Clinical features	T-cell phenotype	Cytotoxic proteins	CD56	Major lineage	EBV
MF	Patches and plaques; (ulcerating) tumors in advanced stage	CD3⁺, CD4⁺, CD8⁻	−	−	αβ T cell	−
C-ALCL	Solitary or localized nodules or tumors	CD3^+/−, CD4⁺, CD8⁻, CD30⁺	+	−	αβ T cell	−
SPTCL	Subcutaneous nodules and plaques	CD3⁺, CD4⁻, CD8⁺	+	−	αβ T cell	−
PCGD-TCL	Ulcerating plaques and tumors	CD3⁺, CD4⁻, CD8^−/+	+	+	γδ T cell	−
Extranodal NK/T-cell lymphoma	(Ulcerating) plaques and tumors	CD3⁺, CD4⁻, CD8⁺ (surface CD3⁻)	+	+	NK or γδ T cell	+
CD8⁺ AECTCL	Ulcerating plaques, nodules, and tumors	CD3⁺, CD4⁻, CD8⁺	+	−	αβ T cell	−
Primary cutaneous acral CD8⁺ T-cell lymphoma	Solitary papule or nodule on acral site (ear; nose)	CD3⁺, CD4⁻, CD8⁺	+/−*	−	αβ T cell	−
Primary cutaneous CD4⁺ small/medium T-cell LPD	Solitary nodule or tumor on the face or upper trunk	CD3⁺, CD4⁺, CD8⁻, CD279/PD-1⁺	−	−	αβ T cell	−

	Clinical features	T-cell phenotype	Cytotoxic proteins	CD56	Major lineage	EBV
MF	Patches and plaques; (ulcerating) tumors in advanced stage	CD3⁺, CD4⁺, CD8⁻	−	−	αβ T cell	−
C-ALCL	Solitary or localized nodules or tumors	CD3^+/−, CD4⁺, CD8⁻, CD30⁺	+	−	αβ T cell	−
SPTCL	Subcutaneous nodules and plaques	CD3⁺, CD4⁻, CD8⁺	+	−	αβ T cell	−
PCGD-TCL	Ulcerating plaques and tumors	CD3⁺, CD4⁻, CD8^−/+	+	+	γδ T cell	−
Extranodal NK/T-cell lymphoma	(Ulcerating) plaques and tumors	CD3⁺, CD4⁻, CD8⁺ (surface CD3⁻)	+	+	NK or γδ T cell	+
CD8⁺ AECTCL	Ulcerating plaques, nodules, and tumors	CD3⁺, CD4⁻, CD8⁺	+	−	αβ T cell	−
Primary cutaneous acral CD8⁺ T-cell lymphoma	Solitary papule or nodule on acral site (ear; nose)	CD3⁺, CD4⁻, CD8⁺	+/−*	−	αβ T cell	−
Primary cutaneous CD4⁺ small/medium T-cell LPD	Solitary nodule or tumor on the face or upper trunk	CD3⁺, CD4⁺, CD8⁻, CD279/PD-1⁺	−	−	αβ T cell	−

PCGD-TCL, primary cutaneous γ/δ T-cell lymphoma; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.

Expresses a nonactivated cytotoxic phenotype, positive for TIA-1, but negative for other cytotoxic proteins.